Followers | 446 |
Posts | 31415 |
Boards Moderated | 4 |
Alias Born | 04/04/2006 |
Monday, October 12, 2015 3:10:08 PM
Settlement Short Interest Avg Daily Days To Cover
9/30/2015 5,186,707 2,226,660 2.329366
9/15/2015 4,555,319 379,266 12.010882
8/31/2015 4,128,377 692,860 5.958458
8/14/2015 4,117,923 353,530 11.648016
7/31/2015 4,328,439 271,973 15.914958
7/15/2015 4,553,229 329,442 13.821034
6/30/2015 4,233,722 371,699 11.390189
6/15/2015 4,180,151 290,939 14.367792
5/29/2015 3,998,166 282,519 14.151848
5/15/2015 3,938,074 432,816 9.098726
4/30/2015 3,741,579 305,662 12.240903
4/15/2015 3,614,541 333,056 10.852652
3/31/2015 3,985,031 715,518 5.569435
3/13/2015 3,859,669 669,132 5.768173
2/27/2015 3,372,408 416,591 8.095249
2/13/2015 2,849,802 692,951 4.112559
1/30/2015 2,524,149 1,019,776 2.475199
1/15/2015 3,265,816 385,817 8.464676
12/31/2014 3,308,416 330,509 10.010063
12/15/2014 3,438,535 193,837 17.739312
11/28/2014 3,418,793 190,413 17.954620
11/14/2014 3,504,995 205,436 17.061250
10/31/2014 3,237,286 213,263 15.179783
10/15/2014 3,234,748 246,241 13.136513
Read more: http://www.nasdaq.com/symbol/vstm/short-interest#ixzz3oNlaLGQk
YOU agree to all this when reading my posts
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114785639
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114785652
Recent VSTM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 08:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 10:01:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 10:00:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:30:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:30:17 PM
- Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference • Business Wire • 09/10/2024 08:05:00 PM
- Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting • Business Wire • 09/10/2024 11:30:00 AM
- Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 • Business Wire • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:10:42 PM
- Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates • Business Wire • 08/08/2024 08:05:00 PM
- Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer • Business Wire • 07/29/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 12:45:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/24/2024 09:06:01 PM
- Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants • Business Wire • 07/24/2024 03:20:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/23/2024 08:33:23 PM
- Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants • Business Wire • 07/23/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:01:17 PM
- Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics • Business Wire • 07/12/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 11:00:18 AM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 07/08/2024 11:30:00 AM
- Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes • Business Wire • 07/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 11:01:58 AM
- Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer • Business Wire • 05/24/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:24:02 PM
- Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer • Business Wire • 05/23/2024 09:01:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM